APAC Seasonal Influenza Market Value to Post 4.7% CAGR to 2022, States GBI Research in Its Discounted Study Available at MarketPublishers.com
16 Feb 2017 • by Natalie Aster
LONDON – In the recent past the demand for seasonal influenza (flu) vaccines have surged due to altered attitudes of patient population.
The Asia-Pacific region is a lucrative market for seasonal flu vaccine producers. Ongoing improvements in vaccine formulation has taken place over the years, with the market presently migrating from trivalent to quadrivalent formulations, which provide prevention of an additional B strain. However, certain unmet needs for these therapies still exist in terms of efficacy and safety. Conventional egg-based production of seasonal flu vaccines is being substituted with cell culture influenza vaccines. Cell culture-based vaccine manufacturing is set to diminish the problems related to the production and use of seasonal flu vaccines, which is projected to further expand the vaccination coverage across the region.
The APAC seasonal flu market is expected to reach a value of USD 1.71 billion by 2022, registering a 4.7% CAGR. The market is likely to be driven by surging awareness, booming elderly population, and the emergence of quadrivalent therapies.
Japan is forecast to account for the majority of the total market value, on account of the introduction of quadrivalent therapies.
Discounted report by GBI Research titled “Seasonal Influenza Therapeutics in Asia-Pacific Markets to 2022” is a reliable, detailed guide to the marketplace on a regional level.
The study provides deep insights into the present-day commercial and clinical disease landscape; carefully examines the structure of the seasonal flu market with respect to dominant treatments alongside highlighting unmet needs to allow in-depth insights into the gaps in today’s market. The report presents a granular, complete overview of the seasonal flu pipeline and categorises pipeline therapies by development phase, molecule type and molecular target. It evaluates the prospects of late-stage treatments, with detailed profiling of products that are anticipated to come into the market in the offing. The report provides projections of the growth and development of the seasonal flu market in the five APAC markets, with epidemiological and yearly cost of therapy forecast figures. Furthermore, major trends in co-development and licensing deals are limelighted as well.
More comprehensive reports by this publisher can be found at GBI Research page.